If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
== History == Nemolizumab was invented by Chugai, who sold an exclusive license for the drug's development and worldwide marketing (except Japan and Taiwan) to Galderma in 2016. The US Food and Drug Administration (FDA) approved nemolizumab for the treatment of prurigo nodularis based on evidence from two clinical trials (OLYMPIA 1 and OLYMPIA 2) of 560 participants with prurigo nodularis. The trials were conducted at 132 sites in 16 countries including Austria, Belgium, Canada, Denmark, France, Netherlands, Germany, Hungary, Italy, Poland, South Korea, Spain, Sweden, Switzerland, the United Kingdom, and the United States. The trials included 99 participants inside the United States. Among the 560 enrolled participants, all of them were evaluated for efficacy (intent-to-treat population) and 556 participants were evaluated for safety. In both trials, participants with prurigo nodularis were randomized to receive nemolizumab or placebo. Participants weighing less than 90 kilograms (200 lb) in the nemolizumab group received subcutaneous injections of nemolizumab 60 mg at week 0, followed by 30 mg injections every four weeks. Participants weighing 90 kilograms (200 lb) or more in the nemolizumab group received subcutaneous injections of nemolizumab 60 mg at week 0 and every four weeks.
=== Firearm offences === 1971: Teo Cheng Leong, a Singaporean robber hanged on an unknown date in May 1971 for shooting at a police officer twice with intent to cause harm. 1975: Liew Ah Chiew, a 19-year-old National Serviceman convicted of murdering his platoon commander Hor Koon Seng and hanged on 29 November 1975. 1976: Sha Bakar Dawood, a Singaporean national, hanged on 3 September 1976 for the use of a firearm with intent to cause injury, after shooting three people at a brothel and then opening fire on police at Thiam Siew Avenue. 1977: Talib bin Haji Hamzah, a Singaporean national, hanged on 28 January 1977 for the use of a firearm with intent to cause injury, after being an accomplice to two jewellers shop robberies in 1974 during which firearms were discharged. 1980: Chang Bock Eng and Tay Cher Kiang, who were both given the death penalty in August 1977 for using a revolver during an armed robbery at a paint shop. Both Chang and Tay were hanged on 9 May 1980. 1984: Lim Kok Yew, a Malaysian national, hanged on 8 June 1984 for the joint enterprise of the use of a firearm with intent to cause injury, after he and his accomplice Yong Kwee Kong took hostages while exchanging fire with police during the Tiong Bahru bus hijacking. 1991: Chia Chee Yeen, a National Serviceman and army lance corporal charged with shooting his army superior to death at an army camp in July 1987. Chia was sentenced to death for murder in May 1990, and he lost his appeal in September 1991. He had been since executed.
=== McClintock's work on maize === Barbara McClintock began her career as a maize cytogeneticist. In 1931, McClintock and Harriet Creighton demonstrated that cytological recombination of marked chromosomes correlated with recombination of genetic traits (genes). McClintock, while at the Carnegie Institution, continued previous studies on the mechanisms of chromosome breakage and fusion flare in maize. She identified a particular chromosome breakage event that always occurred at the same locus on maize chromosome 9, which she named the "Ds" or "dissociation" locus. McClintock continued her career in cytogenetics studying the mechanics and inheritance of broken and ring (circular) chromosomes of maize. During her cytogenetic work, McClintock discovered transposons, a find which eventually led to her Nobel Prize in 1983.
==== Subcellular distribution ==== Enzymes can be compartmentalized, with different metabolic pathways occurring in different cellular compartments. For example, fatty acids are synthesized by one set of enzymes in the cytosol, endoplasmic reticulum and Golgi and used by a different set of enzymes as a source of energy in the mitochondrion, through β-oxidation. In addition, trafficking of the enzyme to different compartments may change the degree of protonation (e.g., the neutral cytoplasm and the acidic lysosome) or oxidative state (e.g., oxidizing periplasm or reducing cytoplasm) which in turn affects enzyme activity. In contrast to partitioning into membrane bound organelles, enzyme subcellular localisation may also be altered through polymerisation of enzymes into macromolecular cytoplasmic filaments.
Sources: en.wikipedia.org
== Early life and education == Born in 1953 and raised in Dearborn, Michigan, Tippett is an alumnus of Kalamazoo College and holds a Ph.D. and M.D. from Case Western Reserve University School of Medicine. He studied at the Rockefeller University in New York under Nobel Prize winner Robert Bruce Merrifield, directing his doctoral research efforts toward the metabolic indicators of peptide synthesis. He completed his internship and residency in Internal Medicine at Cleveland Metropolitan General Hospital, and spent 1975-1985 engaged in biochemical research.
=== Land reform === Segni's appointment seemed to halt Gullo's agrarian reform drive: between September 1946 and December 1947 issued two decrees that allowed landowners to reclaim unimproved lands. This secured the support of southern elites for the Christian Democrat party, enabling it to win the 18 April 1948 general elections. It increased the tension between the two factions and rekindled laborer occupation of uncultivated land. The Massacre of Melissa, took place in Calabria: on 24 October 1949, some 14,000 peasants from Catanzaro and Cosenza, accompanied by women, children and work animals, occupied the large latifundia and began planting. A group of agrarian Calabrian CD parliamentarians went to Rome, protesting and asking Scelba to use force against the peasants. Scelba sent Mobile Units (mechanized riot police), to Calabria, which stopped at Melissa, in Crotone, finding a large number of protesters on the Fragalà estate, owned by Baron Luigi Berlingeri. The land was supposed to be assigned to the municipality, but the Berlingeri family had usurped it. The peasants claimed at least half of it, but the baron was willing to cede only a third. On 29 October 1949, police, after demanding the crowd of peasants to leave, fired at eye level, wounding 15 wounded and killing 3: Giovanni Zito, Francesco Nigro, and Angelina Mauro. This massacre, combined with that of Portella della Ginestra, in Sicily, which took place on 1 May 1947, provoked strikes and peasant demonstrations throughout Italy.
Liraglutide, sold under the brand name Victoza among others, is an anti-diabetic medication used to treat type 2 diabetes, and chronic obesity. It is a second-line therapy for diabetes following first-line therapy with metformin. Its effects on long-term health outcomes like heart disease and life expectancy are unclear. It is given by injection under the skin. Liraglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) also known as incretin mimetics. It works by increasing insulin release from the pancreas and decreases excessive glucagon release. Common side effects include low blood sugar, nausea, dizziness, abdominal pain, and pain at the site of injection. Gastrointestinal side-effects tend to be strongest at the beginning of treatment period and subside over time. Other serious side effects may include angioedema, pancreatitis, gallbladder disease, and kidney problems. Use in pregnancy and breastfeeding is of unclear safety. Liraglutide was approved for medical use in the European Union in 2009, and in the United States in 2010. It is available as a generic medication. In 2023, it was the 209th most commonly prescribed medication in the United States, with more than 2 million prescriptions.
Sources: en.wikipedia.org
=== Ribosomal RNA modification === Ribosomal RNA (rRNA) is essential to the makeup of ribosomes and peptide transfer during translation processes. Ribosomal RNA modifications are made throughout ribosome synthesis, and often occur during and/or after translation. Modifications primarily play a role in the structure of the rRNA in order to protect translational efficiency. Chemical modification in rRNA consists of methylation of ribose sugars, isomerization of uridines, and methylation and acetylation of individual bases.
=== Legal status === In 2013, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended that medicines containing ergot derivatives no longer be used to treat several conditions involving problems with memory, sensation or blood circulation, or to prevent migraine headaches because the risks (increased risk of fibrosis and ergotism) were said to be greater than the benefits in these indications.
29 July – Laura Mackenzie, whose offer of a job with Police Scotland was withdrawn when it emerged she had been prescribed antidepressants, launches legal action against the force. The offer was withdrawn after her medical history came to light during a health examination prior to starting the job, and because Police Scotland requires any recruits to be clear of antidepressant medication for at least two years. 31 July Media outlets, including BBC News, report that a medical student has been expelled from the University of Dundee after filming the dissection of a human body and posting the footage online. The 2023 Rutherglen and Hamilton West recall petition closes. A by-election is triggered after the petition to remove Margaret Ferrier from office is signed by 11,896 of the 81,124 eligible constituents, passing the required 10% threshold.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.